Effect of tadarafil for persistant pulmonary hypertension early after congenital heart surgery in children

Effect of tadarafil for persistant pulmonary hypertension early after congenital heart surgery in children - Effect of tadarafil for PH early after CHD surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013317

Enrollment

Registered

2014-03-03

Start date

2014-03-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congenital heart disease associated with pulmonary hypertension after open heart surgery

Interventions

For intubated children with pulmonary hypertension after open heart surgery,0.5mg/kg of tadarafil will be administered orally, and same dose of tadarafil will be added 12 hours after initial administr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: children younger than 16 years old with persistent pulmonary hypertension early after open heart surgery

Exclusion criteria

Exclusion criteria: case who is administered other drugs for pulmonary hypertension

Design outcomes

Primary

Measure	Time frame
blood pressure, heart rate, pulmonary artery pressure, SpO2, blood concentration of tadarafil (before administration, 2,4,6,8,12,16,20,24 hours after administration)	—

Secondary

Measure	Time frame
presence or absence of adverse event of tadarafil	—

Countries

Japan

Contacts

Public ContactHiroshi Katayama

Osaka Medical College Department of Pediatrics

ped100@poh.osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026